Companies · Biotechnology
PALO ALTO · Biotechnology
Diligence memoA one-page analyst read on Immune-Onc Therapeutics, Inc. — recommendation, valuation, rhythm, risks.→Immune-Onc Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Immune-Onc Therapeutics, Inc. is one of 4293 Biotechnology companies tracked from PALO ALTO. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 50% of sector peers (real $). Modeled value above 75% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #59 of 157.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Bio-Dent, LTD. LLC | Series A | $15.0M | $542.3M | 2.57× |
| Anthera Pharmaceuticals Inc | Series A | $15.0M | $542.3M | 2.57× |
| Cynvec LLC | Series A | $17.4M | $542.3M | 2.57× |
| Biothera Holding Corp. | Series A | $16.2M | $529.3M | 2.51× |
| Limelight Bio, Inc. | Series A | $14.0M | $506.2M | 2.40× |
| Overture Life, Inc. | Series A | $13.6M | $491.7M | 2.33× |
| TAI Diagnostics, Inc. | Series A | $21.1M | $463.8M | 2.20× |
| Occulo Holdings LLC | Series A | $12.8M | $462.7M | 2.19× |
| Agilis Biotherapeutics, Inc. | Series A | $25.7M | $458.0M | 2.17× |
| CAMBRIDGE EPIGENETIX Ltd | Series A | $12.3M | $444.4M | 2.11× |
| Genten Therapeutics, Inc. | Series A | $12.0M | $433.8M | 2.06× |
| LTC BioSciences, Inc | Series A | $12.0M | $433.8M | 2.06× |
| Immune-Onc Therapeutics, Inc. this company | Series A | $7.0M | $253.2M | 1.20× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $7.0M | 2016-07-01 | $31.8M | $253.2M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Guo-Liang Yu | — | 1 other | 2016-07 |
| Liqun Luo | — | — | 2016-07 |
| Xiaoling Charlene Liao | — | — | 2016-07 |
Immune-Onc Therapeutics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Biovest International Inc | Biotechnology | Series A | $7.0M | $253.1M | same sector · same stage |
| Securus Medical Group, Inc. | Biotechnology | Series A | $7.0M | $235.0M | same sector · same stage |
| VADovations, Inc. | Biotechnology | Series A | $7.0M | $180.8M | same sector · same stage |
| BioAesthetics Corp | Biotechnology | Series A | $6.9M | $211.1M | same sector · same stage |
| Phoenix Cardiac Devices, Inc. | Biotechnology | Series A | $7.2M | $179.6M | same sector · same stage |
| KNOW Bio, LLC | Biotechnology | Series A | $7.2M | $260.3M | same sector · same stage |
| BeyondSpring Inc. | Biotechnology | Series A | $7.2M | $261.0M | same sector · same stage |
| Contraline, Inc. | Biotechnology | Series A | $7.2M | $189.4M | same sector · same stage |
See where Immune-Onc Therapeutics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Immune-Onc Therapeutics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.